Skip to main content
    T

    Transcode Therapeutics Inc (RNAZ)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $1.35
    +0.03 (+2.27%)

    Market Cap: $22.35M

    Last updated: Nov 17, 2026 at 11:02 AM ET

    Transcode Therapeutics Inc (RNAZ) Financials: Revenue, Profit and Cash Flow

    Updated Nov 13, 2026. Financial statements from company filings, amounts in US dollars.

    Transcode Therapeutics reported revenue of $0 for the fiscal year ended Dec 31, 2025. That year, net income was -$34.66M, operating cash flow was -$19.52M and free cash flow was -$19.52M. The quarter ended Sep 30, 2026 had revenue of $0 and net income of -$107.38M.

    Revenue and Margins

    The company reported no revenue in the fiscal year ended Dec 2025, with an operating loss of $27.98M.

    Fiscal yearRevenueGrowthGross marginOperating marginNet margin
    Dec 2025$0N/AN/AN/AN/A
    Dec 2024$0N/AN/AN/AN/A
    Dec 2023$0N/AN/AN/AN/A
    Dec 2022$0N/AN/AN/AN/A
    Dec 2021$0N/AN/AN/AN/A
    Dec 2020$0N/AN/AN/AN/A
    Dec 2019$0N/AN/AN/AN/A
    Dec 2018N/AN/AN/AN/AN/A
    Annual, fiscal years ended Dec 2018 to Dec 2025

    Income Statement

    In the fiscal year ended Dec 2025, the net loss widened from the year before. In the quarter ended Sep 2026, the net loss widened from the same quarter a year earlier.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018
    Research and development$13.42M$9.71M$12.26M$10.23M$2.75M$284.46K$226.31K$82.53K
    Operating income-$27.98M-$15.66M-$19.42M-$18.63M-$6.15M-$726.60K-$456.87K-$384.00K
    Net income-$34.66M-$16.75M-$18.55M-$17.56M-$6.84M-$2.34M-$607.21K-$453.44K
    EBITDAN/AN/A-$17.98M-$17.45MN/AN/A-$450.25K-$69.44K
    Fiscal years ended Dec 2018 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Gross profit$0$0$0N/A$0$0$0$284.48K$0$0$0N/A
    Operating income-$109.69M-$6.79M-$17.76M-$16.03M-$4.56M-$4.22M-$3.17M-$5.09M-$2.17M-$5.11M-$3.29M-$4.10M
    Net income-$107.38M-$6.75M-$17.79M-$13.44M-$4.86M-$4.28M-$12.09M-$5.92M-$2.32M-$5.19M-$3.33M-$4.09M
    Last 12 quarters

    Balance Sheet

    As of Dec 2025, cash and equivalents exceeded short-term debt of $0 by $17.81M.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018
    Total assets$162.40M$7.29M$5.17M$7.59M$22.94M$1.06M$216.74K$214.65K
    Current assets$21.98M$7.09M$4.46M$7.38M$22.73M$831.22K$204.47K$214.65K
    Cash and equivalents$17.81M$5.81M$2.77M$4.97M$20.83M$828.02K$204.47K$212.98K
    Total liabilities$10.52M$9.31M$3.53M$4.35M$2.53M$4.46M$1.31M$718.61K
    Short-term debt$0$38.29K$412.28KN/A$2.02MN/AN/A$35.69K
    Long-term debtN/AN/AN/AN/AN/A$2.09M$927.81KN/A
    Shareholder equity$10.34M-$2.02M$1.64M$3.24M$20.40M-$3.41M-$1.10M-$503.97K
    Fiscal years ended Dec 2018 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Total assets$44.75M$151.01M$157.16M$162.40M$5.23M$8.27M$13.19M$7.29M$3.94M$4.82M$7.29M$5.17M
    Total liabilities$12.61M$12.65M$12.64M$10.52M$3.80M$2.12M$2.90M$9.31M$2.28M$3.50M$2.71M$3.53M
    Cash and equivalents$4.64M$8.38M$12.84M$17.81M$2.84M$7.37M$11.57M$5.81M$1.88M$3.35M$4.91M$2.77M
    Shareholder equity$32.14M-$27.69M$1.25M$151.88M$1.43M$6.15M$10.29M-$2.02M$1.65M$1.32M$4.58M$1.64M
    Last 12 quarters

    Cash Flow

    Operating cash flow was negative in the fiscal year ended Dec 2025.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018
    Operating cash flow-$19.52M-$13.34M-$18.07M-$15.76M-$5.27M-$492.97K-$508.51K-$299.57K
    Capital expenditures$6.66K$21.76K$35.61K$100.92K$254.82K$0$254.82K$254.82K
    Free cash flow-$19.52M-$13.36M-$18.11M-$15.86M-$5.52M-$492.97K-$763.33K-$554.39K
    Dividends paid$1.61B$30.60MN/AN/AN/AN/AN/AN/A
    Investing cash flow-$4.44K-$21.76K-$35.61K-$100.92K-$251.82K$0-$251.82K-$251.82K
    Financing cash flow$31.52M$16.40M$15.91M$5.99K$25.52M$1.12M$500.00K$512.43K
    Fiscal years ended Dec 2018 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Operating cash flow-$7.66M-$5.40M-$4.98M-$8.14M-$4.08M-$4.19M-$3.10M-$3.15M-$3.91M-$2.34M-$3.94M-$5.66M
    Capital expendituresN/AN/A$3$6.66K$3$1$500$500$12.87K$4.55K$3.84K$0
    Free cash flowN/AN/A-$4.98M-$8.15M-$4.08M-$4.19M-$3.10M-$3.15M-$3.93M-$2.34M-$3.94M-$5.66M
    Last 12 quarters

    Frequently Asked Questions About RNAZ

    What is Transcode Therapeutics' annual revenue?

    Transcode Therapeutics reported revenue of $0 for the fiscal year ended Dec 31, 2025.

    Is Transcode Therapeutics profitable?

    No. Transcode Therapeutics reported net income of -$34.66M for the fiscal year ended Dec 31, 2025.

    How much free cash flow does RNAZ generate?

    For the fiscal year ended Dec 31, 2025, operating cash flow of -$19.52M minus capital expenditures of $6.66K produced free cash flow of -$19.52M.

    How much debt does Transcode Therapeutics have?

    The balance sheet dated Dec 31, 2025 reported short-term debt of $0 and cash and equivalents of $17.81M.